{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '10.3.5 Procedure and Consequence for Patient Withdrawal From Study', 'The patients may be withdrawn from the study at any time during the course of study if their', 'parent(s)/caregiver(s)/legal guardian(s) decide to do so, and irrespective of the reason.', 'Withdrawal of consent for follow-up should be accompanied by documentation of the reason for', 'withdrawal. Withdrawal of consent for treatment should be distinguished from withdrawal of', 'consent for follow-up visits and from withdrawal of consent for non-patient contact follow-up, eg,', 'medical records checks.', 'For patients who withdraw, the patient and their parent(s)/caregiver(s)/legal guardian(s) should be', 'explicitly asked about the contribution of possible AEs to their decision to withdraw consent, and', 'any AE information elicited should be documented.', 'Patient(s)/parent(s)/caregiver(s)/legal guardian(s) may withdraw consent verbally or in writing', 'and, if verbal, then the site needs to document in source records that patient withdrew consent', 'verbally.', 'If possible, the patients who withdraw consent will be assessed using the procedures normally', 'planned for the EOT visit and have EOS assessments completed at the same visit or at the last', 'planned visit.', 'For patients who fail to return to the site, the Investigator should make the best effort to re-contact', \"the patient (eg, contacting patient's family or private physician, reviewing available registries or\", 'health care databases), and to determine his/her health status, including at least his/her vital status.', \"Attempts to contact such patients must be documented in the patient's records (eg, times and dates\", 'of attempted telephone contact, receipt for sending a registered letter).', 'A subject should only be designated as lost to follow-up, if the site is unable to establish contact', 'with the patient/parent(s)/caregiver(s)/legal guardian(s) after 3 documented attempts via', '2 different methods (phone, text, e-mail, certified letter, etc).', 'The statistical analysis plan (SAP) will specify how these patients lost to follow-up for their', 'primary endpoints will be considered. Patients who have withdrawn from the study cannot be', 'rerandomized (treated) in the study. Their inclusion and treatment numbers must not be reused.', '10.4 OBLIGATION OF THE INVESTIGATOR REGARDING SAFETY REPORTING', '10.4.1 Definitions of Adverse Events', '10.4.1.1 Adverse Event', 'An AE is any untoward medical occurrence in a patient or clinical investigation patient', 'administered a pharmaceutical product and which does not necessarily have to have a causal', 'relationship with this treatment.', 'Property of the Sanofi Group - strictly confidential', 'Page 100', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Protocol-defined severe asthma exacerbation events and LOAC (for detailed definitions see', 'Section 9) are collected as efficacy endpoints on the e-CRF. Only asthma exacerbations which', 'fulfill a seriousness criterion should be reported as an AE (as per Section 10.4.1.2).', 'For this study, asthma exacerbations should be managed by the Investigators based on their', 'medical judgment and applicable national/international asthma management guidelines.', '10.4.1.2 Serious Adverse Event', 'A SAE is any untoward medical occurrence that at any dose:', 'Results in death, or', 'Is life-threatening, or', 'Note: The term \"life-threatening\" in the definition of \"serious\" refers to an event in which', 'the patient was at risk of death at the time of the event; it does not refer to an event which', 'hypothetically might have caused death if it were more severe.', 'Requires inpatient hospitalization or prolongation of existing hospitalization, or', 'Results in persistent or significant disability/incapacity, or', 'Is a congenital anomaly/birth defect', 'Is a medically important event', 'Medical and scientific judgment should be exercised in deciding whether expedited', 'reporting is appropriate in other situations, such as important medical events that may not', 'be immediately life-threatening or result in death or hospitalization but may jeopardize the', 'patient or may require medical or surgical intervention (ie, specific measures or corrective', 'treatment) to prevent one of the other outcomes listed in the definition above.', 'Note: The following list of medically important events is intended to serve as a guideline for', 'determining which condition has to be considered a medically important event. The list is not', 'intended to be exhaustive:', '-', 'Intensive treatment in an emergency room or at home for:', '-', 'Allergic bronchospasm', '-', 'Blood dyscrasias (ie, agranulocytosis, aplastic anemia, bone marrow aplasia,', 'myelodysplasia, pancytopenia, etc),', '-', 'Convulsions (seizures, epilepsy, epileptic fit, absence, etc).', '-', 'Development of drug dependence or drug abuse', '-', 'ALT >3 X ULN + total bilirubin >2 X ULN or asymptomatic ALT increase > -10 X ULN', '-', 'Suicide attempt or any event suggestive of suicidality', '-', 'Syncope, loss of consciousness (except if documented as a consequence of blood', 'sampling)', '-', 'Bullous cutaneous eruptions', 'Property of the Sanofi Group - strictly confidential', 'Page 101', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}